International Journal of Surgery [1] , entitled "TREM1 deficiency attenuates LPS-induced sepsis-associated acute kidney injury by modulating macrophage polarization."The authors conducted a well-structured and comprehensive investigation that clarifies the immunoregulatory role of the triggering receptor expressed on myeloid cells-1 (TREM1) in sepsis-associated acute kidney injury (SA-AKI) and demonstrates that TREM1 deficiency mitigates renal injury by promoting M2 macrophage polarization.From mechanistic interrogation to functional validation, this work offers valuable insights into the pathogenic role of TREM1 in SA-AKI and provides a strong rationale for considering TREM1 as a potential therapeutic target.While we fully acknowledge the scientific value and methodological rigor of this work, several points merit consideration to further strengthen its translational relevance.The authors report significantly elevated urinary sTREM-1 levels in SA-AKI patients, suggesting potential biomarker utility.Previous studies similarly found increased urinary sTREM-1 levels correlated with the risk and severity of AKI [2,3] .However, data from septic patients without AKI remain limited, making it difficult to determine whether elevated sTREM-1 reflects kidney-specific injury or generalized systemic inflammation.Including septic patients without AKI as a comparator group in future studies would improve the assessment of biomarker specificity.Additionally, although experimental data support a renoprotective effect of TREM1 deficiency, clinical evidence regarding altered TREM1 expression or spatial localization in human SA-AKI kidney tissue is scarce.Incorporating renal biopsy or autopsy samples -evaluated using immunohistochemistry or in situ hybridization -would strengthen the histopathological basis of the proposed mechanism and improve translational relevance.